Background: Doxycycline inhibits formation and progression of abdominal aortic aneurysms
(AAAs) in preclinical models of the disease, but it is unclear whether and how this …

Objective: Eradication of Chlamydia pneumoniae infection and inhibition of elastolytic matrix
metalloproteinases with doxycycline have been suggested to reduce the growth rates of …

Objective: Doxycycline has been shown to inhibit aneurysm formation in a rodent model of
abdominal aortic aneurysm (AAA). The doses necessary for this inhibition (6 mg/kg) are …

Importance Abdominal aortic aneurysms affect more than 3% of US older adults. Objective
To test whether doxycycline reduces the growth of abdominal aortic aneurysm over 2 years …

Background: The primary purpose of this study was to evaluate compliance, side effects, and
safety associated with prolonged administration of doxycycline in patients with small …

Treatment with doxycycline suppresses the development of abdominal aortic aneurysms
(AAAs) in experimental animal models, but its use in humans can be accompanied by dose …

Background: Matrix metalloproteinases (MMPs) likely contribute to the degradation of medial
elastin in abdominal aortic aneurysms (AAAs), and tetracycline antibiotics exhibit MMP …

BACKGROUND: The late durability of endovascular aneurysm repair (EVAR) has been
limited by progressive aortic degeneration believed to be mediated by matrix …

Background There is no proven medical approach to attenuating expansion and rupture of
abdominal aortic aneurysms (AAAs). One approach that is currently being investigated is the …

Background—Doxycycline has been shown to effectively inhibit aneurysm formation in
animal models of abdominal aortic aneurysm. Although this effect is ascribed to matrix …